by Clinton Ritchey
National Center for Policy Analysis
July 09, 2014
India’s lack of intellectual property (IP) rights enforcement hinders trade and pharmaceutical innovation, both in India and in the U.S. India is one of the world’s leaders in the generic pharmaceutical drug market. The third largest drug producer in the world, India is also the second largest exporter of generic drugs to the U.S., behind only Canada. Yet over the past two years, the Indian government has made trade between itself and the U.S. much more tense by engaging in a series of policy, regulatory and legal decisions that undermine internationally recognized IP rights and. In doing so, India has shirked its commitments under the World Trade Organization’s (WTO) Trade-Related Aspects of Intellectual Property agreement, which regulates IP rights and copyright laws in 159 WTO member countries. India must adhere to this agreement if any sort of mutually beneficial U.S.-India trade partnership is to be achieved.